

---

## LIFE SCIENCES

### Representative Mergers and Acquisitions Transactions

The following is a list of representative mergers, acquisitions and divestments in which Wiggin and Dana acted as lead counsel for clients in the biotechnology, pharmaceutical and medical device industries. Each transaction is described according to its status upon completion of the transaction.

- Acted as United States counsel to **Swedencare AB**, a veterinary supplies company, in its \$447 million acquisition of **Naturvet**, a leading supplier of pet supplements, and its earlier acquisition of **Vetio Animal Health Group**.
- Represented **Ximedica, LLC**, a medical device development company, in its sale to **Veralent, Inc.**, an affiliate of Summit Partners.
- Represented **AptarGroup, Inc.** in its acquisition of substantially all of the operating assets and proprietary portfolio of **Cohero Health, Inc.**, a digital respiratory health company.
- Represented **CAS Medical Systems, Inc.** in its sale, via cash-out merger, to a subsidiary of **Edwards Lifesciences Corporation**.
- Represented **Olink Proteomics Holding AB** in the sale of **Olink Proteomics** to **Summa Equity**, a Swedish-based private equity firm that focuses on investments in companies that help solve global challenges. Olink Proteomics is a life science company that has developed a unique technology for human biomarker discovery.
- Represented **Cormorant Pharmaceuticals AB** in its stock purchase agreement in connection with the sale to **Bristol-Myers Squibb Company (BMS)** of all of Cormorant's outstanding capital stock and in which BMS obtained full rights to Cormorant's lead antibody candidate, HuMax-IL8. HuMax-IL8 is a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) that represents a complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules. Payments by BMS to the Cormorant equity holders could reach a total of \$520 million if all clinical and regulatory milestones are achieved.
- Represented **Probi AB**, a Swedish publicly traded bioengineering company that develops probiotics, in its \$105 million acquisition of the assets and operations of **TNTGamble, Inc.d/b/a Nutraceutix**, a Washington State-based manufacturer and supplier of probiotics.
- Represented **Gyros AB**, a pioneer in automated nanoliter-scale immunoassays, in its merger with **Protein Technologies AB**, a leading provider of peptide synthesis instrumentation and reagents.
- Represented **Galecto Biotech AB** in its agreement with **Bristol-Myers Squibb Company (BMS)** for the exclusive option to acquire Galecto and gain worldwide rights to its lead asset, TD139, a novel inhaled inhibitor of galectin-3, a product in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions. Under the agreement, Galecto will receive up to US\$444 million if BMS exercises its option and all contingent payments are made.
- Represented **Premacure Holding AB** in the sale to **Shire plc** of Premacure AB, a company that is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare and potentially blinding disorder that inflicts primarily premature infants. Shire purchased Premacure AB for an upfront payment and certain contingent payments based on the achievement of pre-specified development and commercial milestones.
- Represented **CGI Pharmaceuticals, Inc.** in connection with its merger into a wholly-owned subsidiary of **Gilead Sciences, Inc.** in exchange for cash consideration of up to US\$120 million.
- Represented **AlloMek Therapeutics, LLC**, an innovator in MEK-associated orphan diseases, in its acquisition by **Pasithea Therapeutics Corp.**